1 / 11

Both enterovirus 71 (EV71) and coxsackie A16 virus (CA16)

Both enterovirus 71 (EV71) and coxsackie A16 virus (CA16) have been grouped with human enterovirus group A . Both EV71 and CA16 can cause hand-foot-and-mouth disease and herpangina in young people. Infection with only EV71 occasionally leads to severe

ava-horn
Download Presentation

Both enterovirus 71 (EV71) and coxsackie A16 virus (CA16)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Both enterovirus 71 (EV71) and coxsackie A16 virus (CA16) have been grouped with human enterovirus group A. • Both EV71 and CA16 can cause hand-foot-and-mouth disease and herpangina in young people. • Infection with only EV71 occasionally leads to severe diseases such as aseptic meningitis, poliomyelitis-like paralysis, and possible fatal encephalitis in neonates. • EV71 has been regarded as the most important neurotropic enterovirus.

  2. Active immunization with both live avirulent EV71 strain and CA16 induced EV71 specific immunity in newborn mice

  3. Active immunization CA16 induced a weak protective cross-reactivity for EV71 infection. 10~20%

  4. Cross-reactivity between EV71 and CA16. ELISA-based assay

  5. Anti-CA16 immune serum cross-neutralized EV71. Plaque formation assay a Virus a a a

  6. Both EV71 and CA16 immune sera recognized a common band of the viruses 60

  7. Passive immunization with anti-CA16 immune serum partly protected mice against EV71 Day 6 of age of ICR mice, pssively immunized with an I.P. injection of normal sera, CA16, CB3, or EV71 immune sera lethal challenge with EV71/MP4 strain (105 PFU) via oral route

  8. Passive immunization with anti-CA16 immune serum reduced the tissue viral load of challenged mice Day 6 of age of ICR mice, pssively immunized with an I.P. injection of normal sera, CA16, CB3, or EV71 immune sera lethal challenge with EV71/MP4 strain (105 PFU) via oral route aseptically removed tissue samples, weighed, homogenized Plaque assay with RD cells

  9. Discussion: • Live EV71 active immunization reduced the clinical disease and mortality of mice upon lethal challenge with the virulent mouse-adapted EV71 strain. • Antibody-mediated neutralization and perhaps cell-mediated effects were probably essential to the viral clearance and hence clinical disease prevention. • EV71 and CA16 shared some common epitopes, are probably located on the outer capsid proteins.

  10. Vaccine development? • CA16 infection elicited cross-reactivity for EV71 and that memory to CA16 infection could be recalled by either CA16 or EV71 stimulation. • Limited epidemiology data from the CDC in Taiwan support: there was an inverse relationship between the infection rate of CA16 and EV71. • If this hypothesis is validated in a large cohort of patients, then it might provide a strategy for designing a vaccine regimen.

More Related